The stock's fall snapped a two-day winning streak.

In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after ...

Cell Therapy Regenerative medicine Market. The Cell Therapy Regenerative Medicine market is poised for significant growth, driven by advancements in techno ...

Reported a robust objective response rate of 75.5% from the Phase 1 study of NX-5948 in patients with relapsed/refractory CLL/SLL at the 66th ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook. Galapagos NV plans to split into two entities ...

SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR ? Logitech International (SIX: LOGN) today announced financial results for the third quarter of Fiscal Year 2025. Sales were $1.34 billion ...

Study urges industry to be more transparent and fairer in selecting speakers, and to recruit more women to steering ...

Fairfax India Holdings Corporation ("Fairfax India" or the "Company") is pleased to announce the voting results from its special meeting of shareholders held on January 28, 2025 (the "Special Meeting" ...

The leading Crohn's Disease companies such as Janssen, RedHill Biopharma, Amgen, Pfizer, Hoffmann-La Roche, Gilead Sciences, Eli Lilly and Company, Celgene, AstraZeneca, Abbvie, Mesoblast, Alfasigma, ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...